BioSpace News Archive

Terns Pharmaceuticals, Inc. announced that it has granted as of June 1, 2023 equity inducement awards to three new employees under the terms of the 2022 Employment Inducement Award Plan.

Invivoscribe and Complete Genomics announced that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics’ NGS platforms.

Sprout Pharmaceuticals, Inc. a pharmaceutical company specializing in women’s sexual health announced publication of abstract 12015 by the American Society of Clinical Oncology.

Aclaris Therapeutics, Inc. today announced that members of the Aclaris management team will participate in two healthcare investor conferences in June.

Numinus Wellness Inc. today announced that Payton Nyquvest , Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023, at 1:00 p.m. ET / 10:00 a.m. PT.

Seres Therapeutics, Inc. today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:00 a.m. ET in New York City.

X4 Pharmaceuticals, a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, announced that, effective on May 31, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 3,250 restricted stock units of Atara’s common stock to one newly hired employee.

Syndax Pharmaceuticals, Inc. announced that on June 1, 2023 the Company granted inducement awards to purchase up to 397,900 shares of common stock to eighteen new employees under the Company’s 2023 Inducement Plan.

ORIC Pharmaceuticals, Inc. announced that on June 1, 2023, ORIC granted a total of 3,380 non-qualified stock options and 560 restricted stock units to one new non-executive employee who began their employment with ORIC in May 2023.